tiprankstipranks
Unicycive Therapeutics (UNCY)
NASDAQ:UNCY
US Market

Unicycive Therapeutics (UNCY) Income Statement

58 Followers

Unicycive Therapeutics Income Statement

Last quarter (Q3 2023), Unicycive Therapeutics's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q3, Unicycive Therapeutics's net income was $-4.41M. See Unicycive Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 675.00K$ 951.00K-$ 0.00$ 0.00
Cost of Revenue
-----
Gross Profit
$ 675.00K$ 951.00K---
Operating Expense
$ 58.00K$ 19.00M$ 8.98M$ 2.02M$ 1.96M
Operating Income
$ -10.03M$ -18.05M$ -8.98M$ -2.02M$ -1.96M
Net Non Operating Interest Income Expense
$ 410.00K$ -6.00K$ -628.00K$ -244.00K$ -139.00K
Other Income Expense
$ -12.05M-$ -19.00K-$ -63.00K
Pretax Income
$ -7.95M$ -18.06M$ -9.59M$ -2.26M$ -2.17M
Tax Provision
-----
Earnings From Equity Interest Net Of Tax
-----
Net Income Common Stockholders
$ -8.81M$ -18.06M$ -9.59M$ -2.26M$ -2.17M
Basic EPS
$ -1.74$ -1.20$ -0.86$ -0.16$ -0.15
Diluted EPS
$ -1.74$ -1.20$ -0.86$ -0.16$ -0.15
Basic Average Shares
$ 78.16M$ 15.06M$ 11.68M$ 14.50M$ 14.50M
Diluted Average Shares
$ 78.16M$ 15.06M$ 11.68M$ 14.50M$ 14.50M
Dividend Per Share
$ 28.71----
Total Operating Income As Reported
-----
Reported Normalized Basic E P S
-----
Reported Normalized Diluted E P S
-----
Rent Expense Supplemental
-----
Total Expenses
$ 58.00K$ 19.00M$ 8.98M$ 2.02M$ 1.96M
Net Income From Continuing And Discontinued Operation
$ -28.07M$ -18.06M$ -9.59M$ -2.26M$ -2.17M
Normalized Income
$ -6.46M$ -14.27M-$ -2.26M$ -2.10M
Interest Expense
---$ 244.00K$ 139.00K
EBIT
$ -7.89M$ -18.05M$ -8.96M$ -2.02M$ -2.03M
EBITDA
$ -7.65M$ -17.89M$ -8.46M$ -2.02M$ -2.03M
Currency in USD

Unicycive Therapeutics Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis